Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

Summary

This was a Phase 1, open-label, single dose study in healthy male subjects. The goals of this clinical trial were to determine how baxdrostat might be absorbed and metabolized using radioactive \[14C\] labeled baxdrostat. Subjects were administered a single oral dose of 10 mg containing approximately 100 μCi of \[14C\] baxdrostat. Subjects were to be confined to the study site for 9 to 15 days for blood, urine, and feces collections.

Timeline

Start

2021-11-18

Primary completion

2022-01-15

Completion

2022-01-15

Drugs

Indications